[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1960

Effects of Mytatrienediol in Multiple Myeloma, Metastatic Bone Disease, and Osteoporosis

AMA Arch Intern Med. 1960;105(6):905-913. doi:10.1001/archinte.1960.00270180083011

Multiple myeloma mainly affects the skeleton and may cause marked derangement of mineral metabolism. Hypercalciuria is frequently present and hypercalcemia may be a very serious, and at times fatal, complication of the disease. Estrogens have been shown to decrease urinary calcium excretion 1 and to relieve bone pain in metastatic bone disease2 and in osteoporosis.3,4 In the study of the metabolic effects of newer synthetic hormones, it was found that a weak estrogenic compound, 3-methoxy-16α-methyl-1,3,5 (10)-estratriene-16β, 17β-diol, Mytatrienediol, is effective in decreasing urinary calcium excretion, and the incidental observation of relief of bone pain was made in a patient with multiple myeloma.5 The effect of this hormone was further investigated in a larger number of patients afflicted with this disease, especially in regard to relief of bone pain and to changes of urinary calcium excretion. This hormone was also administered to patients with metastatic bone disease caused